121 related articles for article (PubMed ID: 23701126)
1. Pre-transplant utilization of sorafenib is not associated with increased complications after liver transplantation.
Frenette CT; Boktour M; Burroughs SG; Kaseb A; Aloia TA; Galati J; Gaber AO; Monsour H; Ghobrial RM
Transpl Int; 2013 Jul; 26(7):734-9. PubMed ID: 23701126
[TBL] [Abstract][Full Text] [Related]
2. Sorafenib treatment for recurrent hepatocellular carcinoma after liver transplantation.
Sotiropoulos GC; Nowak KW; Fouzas I; Vernadakis S; Kykalos S; Klein CG; Paul A
Transplant Proc; 2012 Nov; 44(9):2754-6. PubMed ID: 23146514
[TBL] [Abstract][Full Text] [Related]
3. Adverse events affect sorafenib efficacy in patients with recurrent hepatocellular carcinoma after liver transplantation: experience at a single center and review of the literature.
Zavaglia C; Airoldi A; Mancuso A; Vangeli M; Viganò R; Cordone G; Gentiluomo M; Belli LS
Eur J Gastroenterol Hepatol; 2013 Feb; 25(2):180-6. PubMed ID: 23044808
[TBL] [Abstract][Full Text] [Related]
4. Phase I adjuvant trial of sorafenib in patients with hepatocellular carcinoma after orthotopic liver transplantation.
Jia N; Liou I; Halldorson J; Carithers R; Perkins J; Reyes J; Yeh M; Stohr E; Rao S; Lin EH
Anticancer Res; 2013 Jun; 33(6):2797-800. PubMed ID: 23749944
[TBL] [Abstract][Full Text] [Related]
5. Safety of liver resection for hepatocellular carcinoma after sorafenib therapy: a multicenter case-matched study.
Barbier L; Fuks D; Pessaux P; Muscari F; Le Treut YP; Faivre S; Belghiti J
Ann Surg Oncol; 2013 Oct; 20(11):3603-9. PubMed ID: 23715965
[TBL] [Abstract][Full Text] [Related]
6. Hepatocellular carcinoma recurrence among liver transplant recipients within the Milan criteria.
Felga G; Evangelista AS; Salvalaggio PR; Curvelo LA; Della Guardia B; Almeida MD; Afonso RC; Ferraz-Neto BH
Transplant Proc; 2012 Oct; 44(8):2459-61. PubMed ID: 23026620
[TBL] [Abstract][Full Text] [Related]
7. Safety and efficacy of sorafenib for the treatment of recurrent hepatocellular carcinoma after liver transplantation.
Waghray A; Balci B; El-Gazzaz G; Kim R; Pelley R; Narayanan Menon KV; Estfan B; Romero-Marrero C; Aucejo F
Clin Transplant; 2013; 27(4):555-61. PubMed ID: 23758296
[TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of combination therapy with everolimus and sorafenib for recurrence of hepatocellular carcinoma after liver transplantation.
De Simone P; Crocetti L; Pezzati D; Bargellini I; Ghinolfi D; Carrai P; Leonardi G; Della Pina C; Cioni D; Pollina L; Campani D; Bartolozzi C; Lencioni R; Filipponi F
Transplant Proc; 2014; 46(1):241-4. PubMed ID: 24507059
[TBL] [Abstract][Full Text] [Related]
9. Worse outcome of sorafenib therapy associated with ascites and Child-Pugh score in advanced hepatocellular carcinoma.
Kim HY; Park JW; Joo J; Kim H; Woo SM; Lee WJ; Kim CM
J Gastroenterol Hepatol; 2013 Nov; 28(11):1756-61. PubMed ID: 23800278
[TBL] [Abstract][Full Text] [Related]
10. Sorafenib as adjuvant therapy for high-risk hepatocellular carcinoma in liver transplant recipients: feasibility and efficacy.
Saab S; McTigue M; Finn RS; Busuttil RW
Exp Clin Transplant; 2010 Dec; 8(4):307-13. PubMed ID: 21143097
[TBL] [Abstract][Full Text] [Related]
11. Sorafenib use in the transplant setting.
Castelli G; Burra P; Giacomin A; Vitale A; Senzolo M; Cillo U; Farinati F
Liver Transpl; 2014 Sep; 20(9):1021-8. PubMed ID: 24809799
[TBL] [Abstract][Full Text] [Related]
12. Recurrence of hepatocellular carcinoma and hepatitis B reinfection in hepatitis B surface antigen-positive patients after liver transplantation.
Saab S; Yeganeh M; Nguyen K; Durazo F; Han S; Yersiz H; Farmer DG; Goldstein LI; Tong MJ; Busuttil RW
Liver Transpl; 2009 Nov; 15(11):1525-34. PubMed ID: 19877207
[TBL] [Abstract][Full Text] [Related]
13. Comparative efficacy of sorafenib versus best supportive care in recurrent hepatocellular carcinoma after liver transplantation: a case-control study.
Sposito C; Mariani L; Germini A; Flores Reyes M; Bongini M; Grossi G; Bhoori S; Mazzaferro V
J Hepatol; 2013 Jul; 59(1):59-66. PubMed ID: 23500153
[TBL] [Abstract][Full Text] [Related]
14. Sorafenib vs surgical resection for hepatocellular carcinoma with macrovascular invasion: A propensity score analysis.
Costentin CE; Decaens T; Laurent A; Nault JC; Paule B; Letoublon C; Luciani A; Calderaro J; Adam R; Bricault I; Amaddeo G; Cherqui D; Mallat A; Samuel D; Duvoux C; Ganne-Carrié N; Roudot-Thoraval F; Vibert E
Liver Int; 2017 Dec; 37(12):1869-1876. PubMed ID: 28609020
[TBL] [Abstract][Full Text] [Related]
15. [Liver transplantation for hepatocellular carcinoma: a report of 60 cases].
Chen GH; Yang Y; Lu MQ; Cai CJ; He XS; Zhu XF; Xu C; Li H; Huang JF
Zhonghua Wai Ke Za Zhi; 2004 Apr; 42(7):413-6. PubMed ID: 15144669
[TBL] [Abstract][Full Text] [Related]
16. Sorafenib in advanced hepatocellular carcinoma: hypertension as a potential surrogate marker for efficacy.
Estfan B; Byrne M; Kim R
Am J Clin Oncol; 2013 Aug; 36(4):319-24. PubMed ID: 22547010
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and safety of sorafenib in combination with mammalian target of rapamycin inhibitors for recurrent hepatocellular carcinoma after liver transplantation.
Gomez-Martin C; Bustamante J; Castroagudin JF; Salcedo M; Garralda E; Testillano M; Herrero I; Matilla A; Sangro B
Liver Transpl; 2012 Jan; 18(1):45-52. PubMed ID: 21932373
[TBL] [Abstract][Full Text] [Related]
18. Liver transplantation for hepatocellular carcinoma: defining the impact of using extended criteria liver allografts.
Facciuto ME; Singh MK; Katta U; Samaniego S; Sharma J; Rodriguez-Davalos M; Sheiner P; Kim-Schluger L; Wolf DC
Transplantation; 2011 Aug; 92(4):446-52. PubMed ID: 21694662
[TBL] [Abstract][Full Text] [Related]
19. Safety and feasibility of using sorafenib in recurrent hepatocellular carcinoma after orthotopic liver transplantation.
Kim R; El-Gazzaz G; Tan A; Elson P; Byrne M; Chang YD; Aucejo F
Oncology; 2010; 79(1-2):62-6. PubMed ID: 21071991
[TBL] [Abstract][Full Text] [Related]
20. Adjuvant treatment of hepatocellular carcinoma after orthotopic liver transplantation: do we really need this?
Fujiki M; Aucejo F; Kim R
Clin Transplant; 2013; 27(2):169-77. PubMed ID: 23216662
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
